We further designed a GSH‐responsive mesoporous silica nano‐formulation (dMSN‐SB) that inhibits intratumoral TGF‐β signaling, promotes TAN polarization toward the anti‐tumor N1 phenotypes, and subsequently enhances pancreatic cancer response to combined IRE and αPD1 therapy. Here, TGFB1 is linked to pancreatic neoplasm.